Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that the Company presented two posters on its investigational anti-cancer candidate, Supinoxin™ (RX-5902), at the American Society for Clinical Oncology (ASCO) 2016 Gastrointestinal Cancers Symposium in San Francisco, California.
The first poster, entitled “RX-5902, a Phosphorylated p68 Targeting Agent to Treat Subjects with Advanced Solid Tumors,” was a ‘Trials in Progress’ poster outlining the design and objectives of the ongoing Supinoxin Phase I open-label clinical trial in cancer patients with solid tumors, which is designed to evaluate the safety, tolerability, dose-limiting toxicities and maximum tolerated dose (MTD) of Supinoxin.
A second poster, entitled “The Anti-Cancer Effects of Supinoxin (RX-5902) in Pancreatic Carcinoma,” presented new preclinical data evaluating the antiproliferative effects of Supinoxin in human pancreatic cell lines and xenograft pancreatic cancer models. In these studies, Rexahn scientists showed that oral administration of Supinoxin in mice at various doses up to 70 mg/kg for 21 days achieved a dose-dependent, clinically meaningful tumor response of greater than 60%. In addition, at the dose of 70 mg/kg daily, 70% of the animals treated with Supinoxin showed a complete regression of their tumor while 70% experienced tumor free survival.
“We continue to be impressed by the accumulating preclinical data suggesting a potent, dose-dependent anti-cancer effect of Supinoxin in various human cancer cell lines,” said Dr. Ely Benaim, Chief Medical Officer for Rexahn Pharmaceuticals. “The additional preclinical data presented at this year’s ASCO GI Symposium evaluating Supinoxin in models of human pancreatic carcinoma support the results we have seen in other human cancer cell lines such as renal cell carcinoma and triple negative breast cancer, which were recently reported at various medical symposia.”
Dr. Benaim continued, “As a highly targeted therapy, with a unique mechanism of action and convenient oral dosing, we believe Supinoxin is among a new class of next generation cancer therapeutics that may offer meaningful benefits to cancer patients. We look forward to commencing a planned Phase Ib/IIa proof-of-concept trial to clinically assess the potential treatment and quality of life benefits of Supinoxin in patients with advanced and often aggressive forms of cancer.” (Original Source)
Shares of Rexahn Pharmaceuticals closed last Friday at $0.3398 . RNN has a 1-year high of $0.85 and a 1-year low of $0.26. The stock’s 50-day moving average is $0.37 and its 200-day moving average is $0.48.
On the ratings front, Roth Capital analyst Joseph Pantginis maintained a Buy rating on RNN, with a price target of $3, in a report issued on November 6. The current price target implies an upside of 782.4% from current levels. According to TipRanks.com, Pantginis has a total average return of -12.2%, a 31.7% success rate, and is ranked #3592 out of 3608 analysts.
Rexahn Pharmaceuticals Inc is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs.